NO20042101L - N-Formylderivater av paroksetin - Google Patents
N-Formylderivater av paroksetinInfo
- Publication number
- NO20042101L NO20042101L NO20042101A NO20042101A NO20042101L NO 20042101 L NO20042101 L NO 20042101L NO 20042101 A NO20042101 A NO 20042101A NO 20042101 A NO20042101 A NO 20042101A NO 20042101 L NO20042101 L NO 20042101L
- Authority
- NO
- Norway
- Prior art keywords
- paroxetine
- compound
- formylparoxetine
- formula
- composition
- Prior art date
Links
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 title abstract 13
- 229960002296 paroxetine Drugs 0.000 title abstract 13
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 abstract 8
- 150000001875 compounds Chemical class 0.000 abstract 5
- -1 paroxetine compound Chemical class 0.000 abstract 4
- 239000002552 dosage form Substances 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 238000012360 testing method Methods 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 238000003556 assay Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 abstract 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33043001P | 2001-10-22 | 2001-10-22 | |
| PCT/NL2002/000654 WO2003044012A1 (en) | 2001-10-22 | 2002-10-15 | N-formyl derivatives of paroxetine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20042101L true NO20042101L (no) | 2004-05-21 |
Family
ID=23289741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20042101A NO20042101L (no) | 2001-10-22 | 2004-05-21 | N-Formylderivater av paroksetin |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US6703408B2 (de) |
| EP (1) | EP1440067B1 (de) |
| AR (1) | AR036860A1 (de) |
| AT (1) | ATE285408T1 (de) |
| AU (1) | AU2002330771A1 (de) |
| CA (1) | CA2464327A1 (de) |
| DE (2) | DE20220955U1 (de) |
| DK (1) | DK1440067T3 (de) |
| ES (1) | ES2230516T3 (de) |
| HU (1) | HUP0401895A2 (de) |
| IL (1) | IL161521A0 (de) |
| NO (1) | NO20042101L (de) |
| NZ (1) | NZ532432A (de) |
| PT (1) | PT1440067E (de) |
| WO (1) | WO2003044012A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6777554B2 (en) | 2001-02-05 | 2004-08-17 | Teva Pharmaceutical Industries Ltd. | Preparation of N-methylparoxetine and related intermediate compounds |
| WO2006018318A1 (en) * | 2004-08-18 | 2006-02-23 | Synthon B.V. | Liquid paroxetine compositions |
| CA2629514A1 (en) * | 2005-11-14 | 2007-05-24 | Auspex Pharmaceuticals, Inc. | Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties |
| US9138430B2 (en) * | 2007-12-27 | 2015-09-22 | Mylan Specialty L.P. | Formulation and method for the release of paroxetine in the large intestine |
| CN109507349A (zh) * | 2017-09-15 | 2019-03-22 | 万全万特制药江苏有限公司 | 液相色谱法分离测定帕罗西汀中间体光学异构体的方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1422263A (en) | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
| ES2058061T3 (es) * | 1985-10-25 | 1994-11-01 | Beecham Group Plc | Derivado de piperidina, su preparacion y su uso como medicamento. |
| GB9325644D0 (en) * | 1993-12-15 | 1994-02-16 | Smithkline Beecham Plc | Novel formulation |
| US5856493A (en) * | 1995-02-06 | 1999-01-05 | Smithkline Beecham Corporation | Process for making novel form of paroxeting hydrochloride anhydrate |
| JP3446468B2 (ja) | 1996-04-15 | 2003-09-16 | 旭硝子株式会社 | ピペリジンカルビノール類の製造方法 |
| EP0812829A1 (de) | 1996-06-14 | 1997-12-17 | Ontogen Corporation | Substituierte Imidazole als Modulatoren für Mehrfachresistenz gegen Medikamente |
| DE69827000D1 (de) | 1997-05-29 | 2004-11-18 | Smithkline Beecham Plc | Neues verfahren |
| GB9810181D0 (en) * | 1998-05-13 | 1998-07-08 | Smithkline Beecham Plc | Novel formulations |
| WO2000026187A1 (en) | 1998-11-02 | 2000-05-11 | Synthon B.V. | Process for producing 4-arylpiperidine-3-carbinols and related compounds |
| US6239126B1 (en) * | 1998-12-17 | 2001-05-29 | American Home Products Corporation | Arylpiperidine and aryl-1,2,5,6-tetra-hydropyridine urea derivatives |
| GB9916392D0 (en) | 1999-07-13 | 1999-09-15 | Smithkline Beecham Plc | Novel process |
| IT1313702B1 (it) | 1999-08-02 | 2002-09-09 | Chemi Spa | Processo per la preparazione di derivati 3-sostituiti di 4-fenil-piperidine. |
| HUP0303827A2 (hu) * | 2000-08-28 | 2004-04-28 | Synthon B.V. | Paroxetinkészítmények és eljárások ezek előállítására |
| US6755653B2 (en) * | 2001-10-25 | 2004-06-29 | Cubic Defense Systems, Inc. | System and method for preventing cheating in a simulated combat exercise |
-
2002
- 2002-10-15 CA CA002464327A patent/CA2464327A1/en not_active Abandoned
- 2002-10-15 NZ NZ532432A patent/NZ532432A/en unknown
- 2002-10-15 DK DK02768169T patent/DK1440067T3/da active
- 2002-10-15 ES ES02768169T patent/ES2230516T3/es not_active Expired - Lifetime
- 2002-10-15 EP EP02768169A patent/EP1440067B1/de not_active Expired - Lifetime
- 2002-10-15 AT AT02768169T patent/ATE285408T1/de not_active IP Right Cessation
- 2002-10-15 PT PT02768169T patent/PT1440067E/pt unknown
- 2002-10-15 DE DE20220955U patent/DE20220955U1/de not_active Expired - Lifetime
- 2002-10-15 DE DE60202381T patent/DE60202381T2/de not_active Expired - Fee Related
- 2002-10-15 IL IL16152102A patent/IL161521A0/xx unknown
- 2002-10-15 WO PCT/NL2002/000654 patent/WO2003044012A1/en not_active Ceased
- 2002-10-15 AU AU2002330771A patent/AU2002330771A1/en not_active Abandoned
- 2002-10-15 HU HU0401895A patent/HUP0401895A2/hu unknown
- 2002-10-21 AR ARP020103949A patent/AR036860A1/es not_active Application Discontinuation
- 2002-10-21 US US10/274,051 patent/US6703408B2/en not_active Expired - Fee Related
-
2004
- 2004-01-20 US US10/759,436 patent/US20040266825A1/en not_active Abandoned
- 2004-01-20 US US10/759,437 patent/US20040147497A1/en not_active Abandoned
- 2004-05-21 NO NO20042101A patent/NO20042101L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20040266825A1 (en) | 2004-12-30 |
| HUP0401895A2 (hu) | 2004-12-28 |
| DE60202381T2 (de) | 2005-12-08 |
| AU2002330771A1 (en) | 2003-06-10 |
| EP1440067B1 (de) | 2004-12-22 |
| EP1440067A1 (de) | 2004-07-28 |
| US6703408B2 (en) | 2004-03-09 |
| DK1440067T3 (da) | 2005-04-11 |
| DE60202381D1 (de) | 2005-01-27 |
| IL161521A0 (en) | 2004-09-27 |
| NZ532432A (en) | 2005-02-25 |
| CA2464327A1 (en) | 2003-05-30 |
| AR036860A1 (es) | 2004-10-06 |
| PT1440067E (pt) | 2005-02-28 |
| US20040147497A1 (en) | 2004-07-29 |
| ES2230516T3 (es) | 2005-05-01 |
| WO2003044012A1 (en) | 2003-05-30 |
| DE20220955U1 (de) | 2004-09-02 |
| US20030125560A1 (en) | 2003-07-03 |
| ATE285408T1 (de) | 2005-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100773622B1 (ko) | 지프라시돈의 제어된 합성법 및 그의 조성물 | |
| Morley et al. | β-Amyloid precursor polypeptide in SAMP8 mice affects learning and memory | |
| Forsling et al. | The effect of 3, 4‐methylenedioxymethamphetamine (MDMA,? ecstasy?) and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus | |
| Bussière et al. | Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Aβ immunotherapy on their clearance | |
| CN105121437B (zh) | 香豆素衍生物和用于治疗囊性纤维化、慢性阻塞性肺病和错误折叠蛋白质病症的方法 | |
| Scheuer et al. | Piracetam improves cognitive performance by restoring neurochemical deficits of the aged rat brain | |
| EP1721609A2 (de) | Pyridylpyrimidinderivate als effektive Verbindungen gegen Prioninfektionen und Prionerkrankungen | |
| JP2002539260A (ja) | アスパルチルプロテアーゼインヒビターを使用して神経変性障害を処置する方法 | |
| Overø | Preliminary studies of the kinetics of citalopram in man | |
| US20110269703A1 (en) | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy | |
| AU655075B2 (en) | N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylamines | |
| HUT70518A (en) | New indol derivatives, pharmaceutical compositions containing them and process for producing them | |
| CA2738884A1 (en) | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy | |
| Taguchi et al. | Inhibition of advanced protein glycation by a Schiff base between aminoguanidine and pyridoxal | |
| US20040048876A1 (en) | Ziprasidone composition and synthetic controls | |
| JPWO2019009355A1 (ja) | 脂質過酸化誘発性疾患の治療薬およびそのスクリーニング方法 | |
| NO20042101L (no) | N-Formylderivater av paroksetin | |
| JP2008538583A (ja) | アパシー症候群を治療するための方法 | |
| JP2001512462A (ja) | Ｎ−置換−１，５−ジデオキシ−１，５−イミノ−ｄ−グルシトール化合物の、肝炎ウイルス感染の治療のための組み合わせ療法における使用 | |
| Marcoli et al. | Trazodone is a potent agonist at 5-HT2C receptors mediating inhibition of the N-methyl-D-aspartate/nitric oxide/cyclic GMP pathway in rat cerebellum | |
| DE69618765T2 (de) | Verwendung von kompocedinderivaten zur inhibierung der bildung oder sekretion von beta-amyloid-protein | |
| DK200300349U3 (da) | Fast farmaceutisk dosisform omfattende amlodipinmaleat | |
| JP2003507721A (ja) | 組成物中のオメプラゾールの異性体比のｆｔ−ラマン分光測定 | |
| JP2003507721A5 (de) | ||
| US20110251160A1 (en) | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy |